Frontier Treatments

ADPKD investigational drugs, gene and precision therapy, cell and tissue engineering, transplant and replacement advances

⚠ Important Reminder

Most therapies on this page are not yet approved and remain in clinical trials, preclinical studies, or conceptual stages. Do not attempt any experimental treatment on your own, including "gene therapy," "stem cell therapy," or "xenotransplantation" obtained from unofficial channels. All treatment decisions should be made jointly with your nephrologist. This page is for understanding research progress only and is not medical advice.

The only disease-modifying drug approved worldwide to slow ADPKD progression is tolvaptan (see Treatment Options). Everything else described here is investigational or emerging technology that may offer future options but is not available now.

Development stage legend: ApprovedClinical trialPreclinicalConcept/early

1. Investigational Drug Pipeline

The following drugs attempt to slow cyst growth or protect kidney function through different mechanisms. Except tolvaptan, none are approved for ADPKD.

Somatostatin analogues (Octreotide / Lanreotide) Clinical trial

Mechanism: activate somatostatin receptors → inhibit adenylate cyclase → lower intracellular cAMP → reduce cyst fluid secretion and cyst growth

Octreotide-LAR and lanreotide are already used for other conditions (e.g., acromegaly, neuroendocrine tumors). In ADPKD:

Octreotide: ALADIN trial series (3-year RCT, Lancet 2013; ALADIN 2, PLOS Med 2017/2018) showed inconsistent results — some slowing of kidney volume growth but limited kidney function protection.
Lanreotide: DIPAK-1 large randomized trial (309 patients, JAMA 2018) found no significant slowing of eGFR decline, with a need to monitor liver cyst infection risk.

Evidence level: B (RCTs exist but do not support routine use) · Not approved for ADPKD.

miRNA-17 inhibitors (RGLS8429 / Farabursen) Clinical trial

Mechanism: antisense oligonucleotide inhibits miR-17 → releases inhibition of PKD1/PKD2 mRNA → upregulates polycystin PC1/PC2 → suppresses cyst growth

RGLS4326 (first generation): completed a proof-of-concept Phase 1 trial (NCT04536688).
RGLS8429 (Farabursen, second generation): ongoing Phase 1/2 multiple-ascending-dose trial (NCT05521191); preliminary data show increased urinary PC1/PC2 and htTKV (height-adjusted total kidney volume) decline in some patients. FDA agreed to use htTKV as an accelerated approval surrogate endpoint; Phase 3 planned.

Evidence level: C (early clinical trial) · Sources: Regulus Therapeutics; Nature Communications 2019; ASN Kidney Week 2024.

PPAR-γ agonists (Pioglitazone) Clinical trial

Mechanism: activate PPAR-γ → downregulate CFTR → reduce cyst fluid secretion; also improve metabolism and inflammation

Completed a single-center randomized, double-blind, placebo-controlled crossover Phase 1/2 safety trial (NCT02697617) in 18 non-diabetic ADPKD patients at 15 mg/day for 12 months; safety acceptable but sample too small to assess efficacy.

Evidence level: C (early safety trial) · Source: Blazer-Yost et al., Clinical Kidney Journal 2021.

HDAC6 inhibitors Preclinical

Mechanism: inhibit histone deacetylase 6 → lower cAMP, reduce CFTR-mediated chloride current → suppress cyst epithelial proliferation

Tubacin, ACY-1215 and others are effective in animal models and in vitro but have not entered clinical trials. A new oral selective HDAC6 inhibitor, GV-001, shows upregulation of PC1 and suppression of human cyst growth in preclinical studies (Wu et al., J Med Chem 2025).

Evidence level: D (preclinical/animal and in vitro) · No human trials yet.

CDK inhibitors (Roscovitine) Preclinical

Mechanism: inhibit cyclin-dependent kinases (CDK) → arrest cyst epithelial cell cycle → reduce proliferation and apoptosis

Effective only in PKD animal models (Bukanov et al., Nature 2006); no ADPKD human clinical trials reported.

Evidence level: D (preclinical) · Source: Bukanov et al., Cell Cycle 2012.

Other targets: CFTR inhibitors / AMPK activators / mTOR inhibitors

CFTR inhibitor GLPG2737 Trial (terminated): Phase 2a MANGROVE trial (NCT04578548) terminated early for lack of significant efficacy.
Metformin (AMPK activator) Concept/early: effective in vitro/animal models; clinical evidence limited and mostly observational. KDIGO 2025 does not recommend it as ADPKD-specific therapy.
PXL770 (direct AMPK allosteric activator) Preclinical: received FDA orphan drug designation; no completed ADPKD clinical trial yet.
mTOR inhibitors (everolimus / sirolimus) Tested but not approved: early/mid-stage trials (NEJM 2010) failed to show kidney function benefit with notable adverse effects; KDIGO 2025 explicitly recommends against.

Evidence level: B-D · See the "Treatments not recommended" section of Treatment Options.

Drug pipeline overview

Drug / target	Mechanism	Stage	Key result
Tolvaptan (V2 receptor antagonist)	Lower cAMP	Approved	Only approved drug to slow ADPKD progression
Lanreotide / Octreotide	Inhibit cAMP	Clinical trial	DIPAK-1 did not significantly slow eGFR decline
RGLS8429 (anti-miR-17)	Upregulate PC1/PC2	Phase 1/2	Preliminary htTKV decline; Phase 3 planned
Pioglitazone (PPAR-γ)	Downregulate CFTR	Phase 1/2	Safety acceptable; efficacy unverified
HDAC6 inhibitors	Lower cAMP/CFTR	Preclinical	Effective in animals/in vitro
Roscovitine (CDK inhibitor)	Arrest cell cycle	Preclinical	Animal models only
GLPG2737 (CFTR inhibitor)	Inhibit fluid secretion	Terminated	Phase 2a no significant efficacy
mTOR inhibitors	Inhibit proliferation	Not recommended	No kidney function benefit shown

2. Gene and Precision Therapy

ADPKD is caused by mutations in PKD1 or PKD2. Gene-level therapy is a frontier research direction, but none of the following is in routine clinical use.

Antisense oligonucleotides (ASO) Concept/early

Mechanism: bind the miR-17 binding site in the PKD1 3′-UTR → block miR-17 inhibition → restore/increase PKD1 mRNA stability and PC1 protein expression

anti-miR-17 ASOs (e.g., RGLS8429, see above) are in early clinical trials. Other ASO strategies remain preclinical/IND-filing stage. Arnatar's ART5 has been approved by China's NMPA for a first-in-human trial.

Evidence level: D (early/preclinical) · Sources: JASN 2025 abstract ART5; NAR 2024.

Gene editing (CRISPR / base editing) Preclinical

Mechanism: use AAV-delivered base editors (ABE) to correct Pkd1 point mutations → restore PC1 function

Demonstrated only in mice and organoid/human iPSC models to reduce cysts and restore PC1; not yet in human trials.

Evidence level: D (preclinical) · Sources: Cheng et al., JASN 2024 abstract; Cell and Bioscience 2024; Cell Stem Cell 2024.

Genotype-guided therapy (truncating vs non-truncating PKD1) Used for prognostic stratification

Mechanism: PKD1 truncating mutations (frameshift/nonsense/splice/large deletion) cause more severe PC1 loss and typically worse prognosis than non-truncating mutations

Median ESRD onset age is about 55 years for PKD1 truncating mutations versus about 67 years for non-truncating (Cornec-Le Gall et al., JASN 2013).
Genotype information is incorporated into the PROPKD score for prognostic stratification and early screening, but cannot yet guide drug choice.

Evidence level: B (used in clinical prognostic assessment) · Source: JCI Insight 2020 (DOI:10.1172/jci.insight.138724).

3. Cell and Tissue Engineering

Stem cell therapy Concept/early

Mechanism: mesenchymal stem cells (MSC) and their conditioned media may improve the kidney microenvironment via anti-inflammatory, anti-fibrotic, and pro-angiogenic effects; they do not directly correct the cyst gene

Only a small Phase 1 safety trial (6 patients, Makhlough et al., Stem Cell Research & Therapy 2017) showed safety but no kidney function improvement. Larger randomized trials are needed.

⚠ Commercial "stem cell cures for PKD" are mostly marketing without rigorous clinical evidence. Do not receive such treatments at unlicensed clinics.

Evidence level: D (very early) · Source: Makhlough et al., 2017.

Kidney organoids Preclinical / research tool

Mechanism: kidney organoids generated from human pluripotent stem cells or patient tissue can carry PKD1/PKD2 mutations and form cysts, enabling high-throughput drug screening

Organoids are a research tool and drug-screening platform, not a therapeutic product. They have already helped identify new drug candidates (e.g., Rho pathway inhibitors).

Evidence level: D (research platform) · Source: Tran et al., Nature Communications 2022.

Bioartificial kidney / nephron progenitor cells Preclinical / prototype

Mechanism: nephron progenitor cells (NPC) can be expanded in vitro and differentiated into nephron structures; a bioartificial kidney combines silicon nanofiltration membranes with living renal tubular epithelial cells to enable implantable continuous kidney replacement

The Kidney Project (UCSF/Vanderbilt) bioreactor survived 7 days in a pig model (Kim et al., Nature Communications 2023). All approaches remain preclinical/engineering prototype stage.

Evidence level: D (preclinical/prototype) · No long-term human clinical trials yet.

4. Transplant and Replacement Advances

When eGFR progresses to the point of needing kidney replacement therapy, the standard options remain kidney transplant, hemodialysis, and peritoneal dialysis. Below are frontier explorations.

Xenotransplantation (pig-to-human kidney) Experimental early clinical

Mechanism: multi-gene-edited pigs (knockout of pig glycogen antigens, inactivation of endogenous retroviruses, insertion of human genes) reduce hyperacute rejection and immune/coagulation incompatibility

World's first living-recipient pig kidney transplant: Massachusetts General Hospital / eGenesis, March 2024 (Slayman case, NEJM 2025).
Second case (with a mechanical heart pump): NYU Langone, April 2024 (Pisano case).

These are compassionate use / expanded access individual cases at an experimental early clinical stage; long-term safety and survival are not yet established and far from routine.

Evidence level: C (case reports) · Sources: NEJM 2025 (DOI:10.1056/NEJMoa2412747); Xenotransplantation 2024.

Implantable artificial kidney (The Kidney Project) Prototype

Mechanism: integrates silicon nanofiltration membranes with a renal tubular epithelial bioreactor, using native blood pressure to filter blood and regulate fluid/electrolytes while avoiding immune rejection

In animal prototype testing; no long-term human clinical trials yet.

Evidence level: D (prototype) · Sources: Kim et al., Nature Communications 2023; UCSF/Vanderbilt Kidney Project.

Wearable / portable dialysis advances Early trial

Wearable Artificial Kidney (WAK, hemodialysis): portable, sorbent-regenerated dialysate; an early feasibility human trial (7 patients, 24 hours, Gura et al., JASN 2016/2017) was paused for technical issues and remains under engineering improvement.
AWAK automated wearable peritoneal dialysis: portable, sorbent tidal PD; 2024 ASN reported 11 patients completing 7 days and 3 completing 30 days with acceptable safety; a pre-pivotal study is underway.

Evidence level: C (early feasibility) · Source: ASN Kidney Week 2024 abstract TH-OR69.

How to think rationally about frontier therapies

"In research" does not mean "available now": drugs in clinical trials may fail or take years to be approved.
A case is not routine: breakthrough cases like xenotransplantation are scientific progress, but risks and long-term effects are unknown.
Beware commercial marketing: be cautious of unofficial clinics promoting "gene therapy" or "stem cell cures" for PKD.
Join legitimate clinical trials: if you want to participate in research, discuss with your nephrologist and use official channels such as ClinicalTrials.gov.
Best action today: using approved therapies properly (tolvaptan, blood pressure control, lifestyle management) and attending regular follow-ups is the most effective way to slow disease progression right now.

⚠ Important Reminder

This page is for understanding ADPKD research progress only and is not medical advice. All treatment decisions should be made jointly by you and your nephrologist. Do not attempt any experimental or unapproved treatment on your own.

Authoritative Institutions & Key Literature

The following are authoritative ADPKD guideline bodies, research institutions, and examples of hospitals listed in publicly registered ADPKD clinical trials. This list does not constitute a ranking or endorsement of any hospital or physician. Key frontier therapy and case papers are listed in the References section below.

Authoritative Guideline & Research Institutions

KDIGO (Kidney Disease: Improving Global Outcomes) — the global authoritative body issuing the ADPKD evaluation and management guideline (2025): KDIGO ADPKD guideline
PKD Foundation (U.S.) — patient education and research advocacy organization: pkdcure.org
Mayo Clinic — origin of the Mayo imaging classification for ADPKD; long-standing ADPKD research: Mayo Clinic PKD
Yale School of Medicine — Somlo lab and others studying PKD1/PKD2 mechanism and ciliary biology: Yale Nephrology research
University of Alabama at Birmingham (UAB) — PKD research and translation center: UAB PKD Research
University of Kansas Medical Center — NIH-funded PKD Research and Translation Core Center: KU PKD Research Center
European PKD Initiative (EPKI) — European patient advocacy and research organization: epki.eu

Chinese Tier-3 Hospitals Participating in ADPKD Clinical Trials (Examples)

The institutions below appear in publicly registered multicenter ADPKD clinical trials and are listed as examples for care or consultation navigation only — not as a ranking or endorsement. Trial recruitment status changes over time; always verify current status via official hospital channels.

Peking University First Hospital (Department of Nephrology) — lead site of the JMKX003142 Phase 2 ADPKD trial (NCT06800651 / CTR20250172)
Shanghai Changzheng Hospital (Naval Medical University) — national lead site for the Venglustat trial (CTR20190456); triptolide formulation study in ADPKD (NCT02115659)
West China Hospital, Sichuan University — participating site in multiple ADPKD multicenter trials
First Affiliated Hospital, Sun Yat-sen University — ADPKD multicenter trial participant
First Affiliated Hospital / Sir Run Run Shaw Hospital, Zhejiang University — ADPKD multicenter trial participants
Chinese PLA General Hospital (First Medical Center) — ADPKD multicenter trial participant
Xiangya Hospital, Central South University — ADPKD multicenter trial participant
Peking Union Medical College Hospital — ADPKD multicenter trial participant

Note: If you wish to join a clinical trial, first discuss eligibility with your nephrologist, then contact hospitals through official hospital channels. Never use unofficial brokers or paid "trial recruitment" channels.

References

KDIGO 2025 Clinical Practice Guideline on the Evaluation and Management of ADPKD — KDIGO. Kidney International, 2025. DOI: 10.1016/j.kint.2024.07.010. View source
DIPAK-1: Lanreotide in ADPKD — Meijer E, et al. JAMA, 2018. View source
ALADIN: Octreotide in ADPKD (3-year RCT) — Caroli A, et al. Lancet, 2013. View source
Anti-miR-17 oligonucleotide RGLS4326 in ADPKD — Lee EC, et al. Nature Communications, 2019. DOI: 10.1038/s41467-019-11983-y. View source
RGLS8429 (Farabursen) Phase 1/2 — NCT05521191 — ClinicalTrials.gov. View source
Pioglitazone in ADPKD (Phase 1/2 safety) — Blazer-Yost BL, et al. Clinical Kidney Journal, 2021. View source
HDAC6 inhibition in ADPKD — Cebotaru L, et al. Kidney International, 2016. View source
Roscovitine in PKD animal models — Bukanov NO, et al. Nature, 2006. View source
GLPG2737 (CFTR inhibitor) MANGROVE Phase 2a — NCT04578548 — ClinicalTrials.gov. View source
mTOR inhibitors (Everolimus) in ADPKD — Serra AL, et al. NEJM, 2010. View source
PKD1 genotype and ESRD age (truncating vs non-truncating) — Cornec-Le Gall E, et al. JASN, 2013. View source
Mesenchymal stem cell therapy in ADPKD (Phase 1) — Makhlough A, et al. Stem Cell Research & Therapy, 2017. View source
ADPKD kidney organoids for drug screening — Tran T, et al. Nature Communications, 2022. View source
The Kidney Project bioreactor (pig model, 7-day survival) — Kim S, et al. Nature Communications, 2023. DOI: 10.1038/s41467-023-39888-2. View source
First living-recipient pig kidney transplant (Slayman, MGH/eGenesis) — NEJM, 2025. DOI: 10.1056/NEJMoa2412747. View source
Wearable artificial kidney (WAK) pilot — Gura V, et al. JASN, 2016. View source

🐛 Found an error in this page? Tell us

Evidence level: B-D (mostly clinical trials/preclinical/case reports)
Audience: adult ADPKD patients and families interested in research progress
Limitations: most frontier therapies are not approved; research progresses rapidly and some information may be outdated. Always rely on your nephrologist's advice and the latest clinical guidelines. This page is not medical advice.

← Back to Knowledge Base